Screener
R&D at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Tango Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Tango Therapeutics’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 4:15 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-221656
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Collaboration revenue | — | $5,392 |
| Operating expenses: | ||
| Research and development | 33,534 | 36,442 |
| General and administrative | 15,235 | 11,480 |
| Total operating expenses | 48,769 | 47,922 |
| Loss from operations | (48,769) | (42,530) |
| Other income: | ||
| Interest income | 2,177 | 1,614 |
Item 1. Financial Statements.
FAQ
- What is Tango Therapeutics's R&D?
- Tango Therapeutics (TNGX) reported R&D of $33.53M in Q1 2026.
- How has Tango Therapeutics's R&D changed year-over-year?
- Tango Therapeutics's R&D decreased by 8.0% year-over-year, from $36.44M to $33.53M.
- What is the long-term trend for Tango Therapeutics's R&D?
- Over 4 years (2021 to 2025), Tango Therapeutics's R&D has grown at a 14.2% compound annual growth rate (CAGR), from $77.64M to $132.17M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.
Ask your AI about Tango Therapeutics's r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude